Evaluation of Effectiveness of Treatment Paradigm for Newly Diagnosed Type 2 Diabetes Patients in China
NEW2D
1 other identifier
observational
5,000
1 country
2
Brief Summary
This is a study to gain better understanding on how those patients who are newly diagnosed with type 2 diabetes are treated and monitored. The study will record information such as type of therapy, therapeutic outcomes, and patients' satisfaction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2012
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 1, 2012
CompletedFirst Posted
Study publicly available on registry
February 3, 2012
CompletedStudy Start
First participant enrolled
April 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2014
CompletedFebruary 15, 2013
February 1, 2012
1.5 years
February 1, 2012
February 13, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The primary endpoint of this study is the overall proportion of patients whose HbA1c is less than 6.5%, measured at the end of one year follow up.
12 months
Secondary Outcomes (2)
The proportions of patients receiving various regimen, and the duration of each regimen
12 months
The clinical effectiveness of each regimen measured by the proportion of patients reaching the target glycemic control
12 months
Study Arms (1)
Diagnosed within 6 months
No (test) intervention to be adminisitered
Eligibility Criteria
Subjects seen at outpatient clinics of tier 1, 2, and 3 hospitals across the 6 major geographic regions
You may not qualify if:
- Patients who are not willing or not able to return to the same hospital for follow up visits every 3 months for one year after enrollment (e.g. do no reside locally)
- Patients who are participating in another interventional clinical trials
- Patients who are not willing to sign informed consent form
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- China Cardiometabolic Registrieslead
- Bristol-Myers Squibbcollaborator
- VitalStrategic Research Institutecollaborator
Study Sites (2)
People's Hospital of Peking University
Beijing, China
Xijing Hospital
Xi'an, China
Related Publications (2)
Luo Y, Wu H, Liao X, Zhao T, Cui N, Li A, Sun X, Zhang P, Huang Y, Zhang X, Yin H, Ji L. A Guideline-Based Decision Tree Achieves Better Glucose Control with Less Hypoglycemia at 3 Months in Chinese Diabetic Patients. Diabetes Ther. 2021 Jul;12(7):1887-1899. doi: 10.1007/s13300-021-01075-1. Epub 2021 May 29.
PMID: 34050897DERIVEDCai X, Hu D, Pan C, Li G, Lu J, Ji Q, Su B, Tian H, Qu S, Weng J, Zhang D, Xu J, Ji L. The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study. Sci Rep. 2019 May 22;9(1):7709. doi: 10.1038/s41598-019-44169-4.
PMID: 31118445DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Linong Ji, MD
Peking University People's Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 1, 2012
First Posted
February 3, 2012
Study Start
April 1, 2012
Primary Completion
October 1, 2013
Study Completion
January 1, 2014
Last Updated
February 15, 2013
Record last verified: 2012-02